A Phase 1, Randomized, Placebo controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ACP-014 in Healthy Adult Subjects (ACP-014 -Phase 1)
Phase of Trial: Phase I
Latest Information Update: 08 Jan 2018
At a glance
- Drugs TransCon PTH (Primary)
- Indications Hypoparathyroidism
- Focus Adverse reactions; First in man
- Sponsors Ascendis Pharma Bone Diseases
- 08 Jan 2018 According to an Ascendis Pharma media release, the company anticipates to present data from this trial throughout 2018.
- 08 Jan 2018 Initial pharmacokinetic data presented in an Ascendis Pharma media release.
- 06 Oct 2017 New trial record